Page last updated: 2024-12-10

nateglinide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5311309
CHEMBL ID783
CHEMBL ID2114389
CHEBI ID31897
CHEBI ID94617
SCHEMBL ID303827
SCHEMBL ID22088
SCHEMBL ID7880361
SCHEMBL ID13753829
SCHEMBL ID9232138
MeSH IDM0353981

Synonyms (151)

Synonym
AC-1690
BIDD:GT0257
AKOS005577723
AB00639979-08
AKOS015841612
ym-026
djn-608
sdz-djn-608
a-4166 ,
starsis
ay-4166
fastic
trazec
starlix
nateglinide [inn]
trans-n-((4-(1-methylethyl)cyclohexyl)carbonyl)-d-phenylalanine
(-)-n-(trans-4-isopropylcyclohexanecarbonyl)-d-phenylalanine
d-phenylalanine, n-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-
d-phenylalanine, n-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-
ay 4166
a 4166
sdz-djn 608
105816-04-4
nateglinide
MLS001424043
MLS000759500
smr000466372
DB00731
D01111
starsis (tn)
nateglinide (jp17/usp/inn)
senaglinide
n-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-d-phenylalanine
djn 608
HMS2089A10
HMS2051G20
chebi:31897 ,
nsc-758695
sdz djn 608
d-nateglinide
ay4166
CHEMBL783 ,
STK647123
(2r)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
(2r)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid;nateglinide
A801324
A4166 ,
bdbm50344967
2-[(4-isopropyl-cyclohexanecarbonyl)-amino]-3-phenyl-propionic acid
cas-105816-04-4
dtxsid9040687 ,
tox21_111432
dtxcid7020687
n-[(trans-4-isopropylcyclohexyl)carbonyl]-d-phenylalanine
N0912
HMS2235O08
AKOS015960899
CCG-100898
nateglinide [usan:usp:inn:ban]
nsc 758695
41x3pwk4o2 ,
unii-41x3pwk4o2
CHEMBL2114389
MLS003915639
NCGC00271534-03
nateglinide [ep monograph]
nateglinide [who-dd]
nateglinide [mart.]
nateglinide [mi]
nateglinide [jan]
nateglinide [usp monograph]
nateglinide [vandf]
nateglinide [ema epar]
nateglinide [usan]
nateglinide [orange book]
nateglinide [usp-rs]
S2489
(2r)-3-phenyl-2-{[(1r,4r)-4-(propan-2-yl)cyclohexyl]formamido}propanoic acid
gtpl6833
105746-37-0
n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenyl alanine
AB00639979-11
BBL033469
HY-B0422
SCHEMBL303827
AB00639979-06
MLS006011429
NC00148
SCHEMBL22088
tox21_111432_1
NCGC00178741-03
KS-5143
OELFLUMRDSZNSF-BRWVUGGUSA-N
AB00639979-09
SCHEMBL7880361
SCHEMBL13753829
trans-n-{[4-(1-methylethyl)cyclohexyl]carbonyl}-d-phenylalanine
nateglinida
nateglinidum
Q-201449
SCHEMBL9232138
n-[[4-(1-methylethyl)cyclohexyl]carbonyl]-d-phenylalanine
d-phenylalanine, n-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-
(2r)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid
nateglinide, starlix
AB00639979_12
n-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-d-phenylalanine
mfcd00875706
d-phenylalanine, n-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis-
105816-06-6
A1-02996
nateglinide cis impurity
((1r,4r)-4-isopropylcyclohexane-1-carbonyl)-d-phenylalanine
nateglinide, united states pharmacopeia (usp) reference standard
CHEBI:94617
n-[[cis-4-(1-methylethyl)cyclohexyl]carbonyl]-d-phenylalanine(nateglinide impurity)
nateglinide, european pharmacopoeia (ep) reference standard
nateglinide, >=98% (hplc), solid
HMS3715F12
(trans-4-isopropylcyclohexane-1-carbonyl)-d-phenylalanine
SW197528-2
n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
(r)-2-((1r,4r)-4-isopropylcyclohexane
carboxamido)-3-phenylpropanoic acid
Q27166439
(2r)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid
nateglinide (starlix)
HMS3675G17
(r)-2-((1r,4r)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid
n-(trans-4-isopropylcylolohexylcarboxyl)-d-phenylpropylicacid
(r)-2-rel-((1r,4r)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid
Q2254797
BCP28400
NCGC00271534-02
nateglinide impurity c [ep impurity]
nateglinide cis-isomer [usp impurity]
(r)-2-rel-((1r,4r)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoicacid
EN300-303645
n-((cis-4-(1-methylethyl)cyclohexyl)carbonyl)-d-phenylalanine
d-phenylalanine, n-((cis-4-(1-methylethyl)cyclohexyl)carbonyl)-
nateglinide impurity c [ep]
n-((cis-4-isopropylcyclohexyl)carbonyl)-d-phenylalanine
nateglinide cis-isomer [usp]
d-phenylalanine, n-((4-(1-methylethyl)cyclohexyl)carbonyl)-, cis-
xtm4dqp5s5 ,
unii-xtm4dqp5s5
nateglinide impurity c
(2r)-3-phenyl-2-{[4-(propan-2-yl)cyclohexyl]formamido}propanoic acid
EN300-27126236
Z1514053266
{n}-[({trans}-4-isopropylcyclohexyl)carbonyl]-d-phenylalanine

Research Excerpts

Overview

Nateglinide is a fast-acting insulin secretion agent that specifically targets postprandial hyperglycemia in patients with type 2 diabetes. It shows low and pH-dependent solubility that may reduce its oral bioavailability.

ExcerptReferenceRelevance
"As nateglinide is a dipeptide-like drug, we investigated the interaction of nateglinide with peptide transporters PEPT1 and PEPT2, which mediate the absorption of various peptide-like drugs."( Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2.
Hashimoto, Y; Inui, K; Saito, H; Sawada, K; Terada, T, 2000
)
1.07
"Nateglinide is a meglitinide used for the treatment of type 2 diabetes mellitus. "( Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus.
Alrokayan, SA; Hussain, T; Kutala, VK; Naushad, SM, 2022
)
2.41
"Nateglinide is a non-sulphonylurea insulinotropic oral antidiabetic agent. "( I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing.
Bruni, G; Canobbio, A; Cardini, A; Conte, U; Maggi, L; Maietta, M, 2013
)
2.07
"Nateglinide is an oral antidiabetic agent that should be administered 10-30 min before the meal, but it shows low and pH-dependent solubility that may reduce its oral bioavailability. "( II. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: co-milling.
Bruni, G; Canobbio, A; Cardini, A; Conte, U; Maggi, L; Maietta, M, 2013
)
2.07
"Nateglinide is a fast-acting insulin secretion agent that specifically targets postprandial hyperglycemia in patients with type 2 diabetes. "( Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
Ball, M; Dickinson, S; Hershon, K; Holmes, D; Saloranta, C, 2002
)
2.07
"Nateglinide is an amino acid derivative."( Insulin secretagogues.
Davies, MJ, 2002
)
1.04
"Nateglinide (NAT) is a novel insulinotropic agent with a primarily site of action at beta-cell K(ATP) channels, which is common to the structurally diverse drugs like repaglinide (REP) and the SUs."( Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas.
Dunning, BE; Hu, S; Wang, S, 2001
)
1.37
"Nateglinide is a recently approved antidiabetic that suppresses postprandial hyperglycemia by stimulating the early phase of insulin secretion."( Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
Kawamori, R; Kitahara, Y; Mine, T; Miura, K; Okano, A, 2002
)
2.48
"Nateglinide (NA) is a novel oral mealtime glucose regulator, recently approved for the treatment of type II diabetes mellitus. "( Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection.
Bauer, S; Brockmöller, J; Kirchheiner, J; Michael, C; Roots, I; Störmer, E, 2003
)
2.02
"Nateglinide is a new oral antidiabetic agent that stimulates insulin release promptly after its pre-meal administration in a strongly glucose-dependent fashion. "( Nateglinide (Starlix): update on a new antidiabetic agent.
Dunning, BE; Phillips, LS,
)
3.02
"Nateglinide is a phenylalanine derivative that blocks K+ channels in pancreatic beta-cells, facilitating insulin secretion."( Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod, JF, 2004
)
1.34
"Nateglinide is a novel rapid- and short-acting insulin secretagogue that ameliorates postprandial hyperglycemia by improving insulin secretory dynamics to a near normal level more effectively than sulfonylureas. "( Indication for nateglinide in type 2 diabetes mellitus.
Kanda, K; Kishikawa, H; Okada, Y; Tanaka, Y, 2005
)
2.12
"Nateglinide is a D-phenylalanine derivative that stimulates fast insulin secretion with a short activity span. "( Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
González-Ortiz, M; Hernández-Salazar, E; Martínez-Abundis, E,
)
1.83
"Nateglinide is an oral antidiabetic medication that acts through rapid, short-term stimulation of insulin production. "( Postmarketing surveillance study of nateglinide in Japan.
Iso, T; Iwamoto, K; Kajiura, T; Maki, T; Taki, H,
)
1.85
"Nateglinide is an oral antidiabetic medication (OAD) that acts through rapid, short-term stimulation of insulin production. "( Postmarketing study of nateglinide in Japan: treatment of medication-naïve patients with type 2 diabetes.
Iso, T; Kajiura, T; Maki, T; Taki, H; Tanabe, S,
)
1.88
"Nateglinide is a new quick action/short duration (QRSD) type of oral blood glucose regulator, and nateglinide immediate release tablets are used for patients with mild diabetes under the trade name of Fastic((R)) tablets. "( Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
Makino, C; Ninomiya, N; Okano, A; Orita, H; Sakai, H; Yabuki, A, 2006
)
1.98
"Nateglinide is an oral antidiabetic medication that acts through rapid, short-term stimulation of insulin production. "( Study of nateglinide in Japan: long-term treatment of patients with type 2 diabetes.
Iso, T; Iwamoto, K; Kajiura, T; Maki, T; Taki, H,
)
1.99
"Nateglinide is a meglitinide analogue with antidiabetic action. "( Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.
Fan, L; Han, CT; He, YJ; Hu, DL; Li, Q; Liu, ZQ; Tan, ZR; Wang, D; Yu, BN; Zhang, W; Zhang, WX; Zhou, HH, 2006
)
2.01
"Nateglinide is a rapid acting insulin secretagogue inducing an EIR after a meal."( Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Hartmann, A; Haukereid, C; Hjelmesaeth, J; Jenssen, T; Løvik, A; Voytovich, MH,
)
2.3
"Nateglinide is an antidiabetic agent metabolized by CYP2C9 and CYP3A4; hence inhibitors of these CYP isozymes may interact with nateglinide. "( Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies.
Koizumi, T; Mihara, R; Okudaira, K; Takanohashi, T, 2007
)
2.05
"Nateglinide is a derivative of the amino acid D-phenylalanine, which acts directly on the pancreatic beta-cells to stimulate insulin secretion."( A review of nateglinide in the management of patients with type 2 diabetes.
Katsilambros, N; Tentolouris, N; Voulgari, C, 2007
)
1.44
"Nateglinide is an effective and safe drug in treating type 2 diabetes."( [Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
Chen, L; Ding, GX; Guo, Y; Hou, WK; Hu, GL; Ji, QH; Li, QF; Li, YX; Luo, R; Wang, H; Wang, PN; Wang, SJ; Zhang, NY; Zhang, YP, 2008
)
2.05
"Nateglinide (A-4166) is an amino acid derivative with insulinotrophic action in clinical development for treatment of type 2 diabetes. "( Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Bell, PA; Boettcher, BR; Dunning, BE; Fanelli, B; Geisse, S; Hu, S; Schmitz, R; Wang, S, 2000
)
1.98
"Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby stimulates the prandial release of insulin. "( Nateglinide.
Dunn, CJ; Faulds, D, 2000
)
3.19
"Nateglinide, which is a derivative of D-phenylalanine, is a non-sulfonylurea insulin secretagogue."( [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
Ikenoue, T; Kondo, N, 2000
)
1.31
"Nateglinide is an oral hypoglycemic agent approved for use alone or in combination with metformin as an adjunct to diet and exercise for the treatment of type 2 diabetes mellitus."( Nateglinide.
Halas, CJ, 2001
)
2.47
"Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby restores first phase insulin response in patients with Type 2 diabetes."( Nateglinide: a new rapid-acting insulinotropic agent.
Hanif, W; Kumar, S, 2001
)
2.47
"Nateglinide is a novel nonsulfonylurea oral antidiabetic agent that stimulates insulin secretion from the pancreas. "( Nateglinide therapy for type 2 diabetes mellitus.
Baker, DE; Campbell, RK; Levien, TL; White, JR, 2001
)
3.2
"Nateglinide is a new, fast-onset, short-acting hypoglycemic agent, which increases early phase insulin secretion and the total amount of insulin secreted. "( Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
Iwamoto, Y; Omori, Y; Takizawa, T; Teno, S; Uto, Y, 2002
)
2.03
"Nateglinide is a novel insulinotropic agent for the treatment of type 2 diabetes. "( Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
Hu, S, 2002
)
2.11

Effects

Nateglinide has an excellent safety and tolerability profile. Its efficacy in reducing HbA1c in monotherapy (120 mg before meals) is comparable to that of metformin, sulphonylureas, thiazolidinediones or acarbose.

ExcerptReferenceRelevance
"Nateglinide has an excellent safety and tolerability profile, and its efficacy in reducing HbA1c in monotherapy (120 mg before meals) is comparable to that of metformin, sulphonylureas, thiazolidinediones or acarbose (-0.5 to -1.5%)."( Nateglinide (Starlix): update on a new antidiabetic agent.
Dunning, BE; Phillips, LS,
)
2.3
"Nateglinide has an excellent safety and tolerability profile and provides a lifetime flexibility that other antidiabetic agents could not accomplish."( A review of nateglinide in the management of patients with type 2 diabetes.
Katsilambros, N; Tentolouris, N; Voulgari, C, 2007
)
1.44
"Nateglinide has an excellent safety and tolerability profile, and its efficacy in reducing HbA1c in monotherapy (120 mg before meals) is comparable to that of metformin, sulphonylureas, thiazolidinediones or acarbose (-0.5 to -1.5%)."( Nateglinide (Starlix): update on a new antidiabetic agent.
Dunning, BE; Phillips, LS,
)
2.3
"Nateglinide has less hypoglycemic potential than glyburide, suggesting that nateglinide may be a more appropriate insulinotropic agent for patients with moderate fasting hyperglycemia, such as elderly patients and those with comorbid cardiac ischemia."( Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.
Baron, MA; Cefalu, W; Fonseca, VA; Gerich, JE; Hsia, S; Kelley, DE; Nestler, JE; Purkayastha, D, 2004
)
1.34
"Nateglinide has an excellent safety and tolerability profile and provides a lifetime flexibility that other antidiabetic agents could not accomplish."( A review of nateglinide in the management of patients with type 2 diabetes.
Katsilambros, N; Tentolouris, N; Voulgari, C, 2007
)
1.44

Actions

Both nateglinide and acarbose increase post-prandial ghrelin suppression. NateglinIDE did, however, increase the risk of hypoglycemia.

ExcerptReferenceRelevance
"Nateglinide did, however, increase the risk of hypoglycemia."( Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J, 2010
)
1.48
"Both nateglinide and acarbose increase post-prandial ghrelin suppression. "( Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients.
Li, H; Lu, W; Yin, X; Yuan, H; Zheng, F; Zhou, J,
)
0.91

Treatment

Nateglinide treatment resulted in dose-dependent reductions in the mean postprandial glucose response and at the 120-mg dose in fasting glucose. In nateglinides/metformin-treated patients, mean A1C was 8.4% at baseline and 6.9% at week 104.

ExcerptReferenceRelevance
"In nateglinide-treated patients, fasting plasma glucose levels decreased by 0.7 mmol/l, 2-h postprandial glucose levels decreased by 2.7 mmol/l, and 30-min insulin levels increased by 165 pmol/l compared with no changes from baseline of these parameters with placebo added to rosiglitazone (P < 0.001)."( Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Foley, JE; Fonseca, V; Grunberger, G; Gupta, S; Shen, S, 2003
)
1.21
"Nateglinide treatment resulted in dose-dependent reductions in the mean postprandial glucose response and at the 120-mg dose in fasting glucose."( Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
Ferrannini, E; Foley, JE; Gastaldelli, A; Mari, A; Pratley, RE, 2005
)
1.27
"In nateglinide/metformin-treated patients, mean A1C was 8.4% at baseline and 6.9% at week 104. "( PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
Baron, MA; Gerich, J; Jean-Louis, L; Purkayastha, D; Raskin, P, 2005
)
1.18
"One nateglinide/metformin-treated patient experienced a mild hypoglycaemic episode compared with eight episodes in eight patients on glyburide/metformin; one severe episode led to discontinuation."( Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Baron, MA; Gerich, JE; Jean-Louis, L; Marcellari, A; Purkayastha, D; Schwarz, SL, 2008
)
2.27
"Nateglinide treatment produced lower average plasma glucose concentrations in the 0- to 2-h postdose interval than either dose of repaglinide and placebo (P < 0.05 vs."( Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
Kalbag, JB; McLeod, JF; Nedelman, JR; Walter, YH, 2001
)
1.31
"Treatment with nateglinide or repaglinide was characterized by a higher incidence of hypoglycaemia at the beginning of treatment."( Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L, 2009
)
0.9
"Treatment with nateglinide was followed by a significant decrease in mean two-h plasma glucose from 10.5 mmol/L (3.1) to 7.6 mmol/L (2.1; p < 0.001) and a decline in total postprandial area under the curve (AUC) of glucose concentration (p < 0.001). "( Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Hartmann, A; Haukereid, C; Hjelmesaeth, J; Jenssen, T; Løvik, A; Voytovich, MH,
)
1.93
"Treatment with nateglinide plus metformin for up to 12 months was not associated with weight gain."( Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S; Tang, P, 2007
)
2.12

Toxicity

Nateglinide was not associated with hypoglycemia or other adverse events. Only one subject on nateglinides and metformin was withdrawn due to the side effect of hypoglycaemia.

ExcerptReferenceRelevance
" In sum, nateglinide is a safe and effective therapeutic option for treatment of patients with mild to moderate fasting hyperglycemia."( Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
Ball, M; Dickinson, S; Hershon, K; Holmes, D; Saloranta, C, 2002
)
1.04
" The frequency of adverse effects was low and no serious adverse effects were encountered."( Efficacy and safety of nateglinide in the treatment of type II diabetes mellitus.
Chandrasekharan, S; Desai, A; Ganesan, R; Jain, SD; Jayaram, S; Rao, PP, 2002
)
0.63
" Nateglinide was not associated with hypoglycemia or other adverse events."( Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
Abrahamian, H; Dzien, A; Francesconi, M; Loiskandl, A; Prager, R; Weitgasser, R, 2004
)
1.45
" Only one subject on nateglinide and metformin was withdrawn due to the side effect of hypoglycaemia."( Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
Atkin, SL; Robertson, D; Weaver, JU, 2004
)
2.09
"These data demonstrate that nateglinide is a safe and effective agent in treatment to target in patients with T2Dm up to an age of 84 years."( Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
Atkin, SL; Robertson, D; Weaver, JU, 2004
)
2.06
"3%) patients and 80 events as adverse drug reactions in 66 (1."( Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.
Layton, D; Shakir, SA; Twaites, B; Wilton, LV, 2007
)
0.74
" No severe adverse events were noted."( [Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
Chen, L; Ding, GX; Guo, Y; Hou, WK; Hu, GL; Ji, QH; Li, QF; Li, YX; Luo, R; Wang, H; Wang, PN; Wang, SJ; Zhang, NY; Zhang, YP, 2008
)
0.6
"Nateglinide is an effective and safe drug in treating type 2 diabetes."( [Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
Chen, L; Ding, GX; Guo, Y; Hou, WK; Hu, GL; Ji, QH; Li, QF; Li, YX; Luo, R; Wang, H; Wang, PN; Wang, SJ; Zhang, NY; Zhang, YP, 2008
)
2.05

Pharmacokinetics

Nateglinide is an amino acid derivative that improves early phase insulin secretion and reduces mealtime glucose excursions. The time to reach Cmax (tmax) and the elimination half-life of nateglinides were similar between the two treatments.

ExcerptReferenceRelevance
" The effects of a meal on the oral bioavailability and pharmacodynamic actions of nateglinide were investigated."( The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
Dunning, BE; Karara, AH; McLeod, JF, 1999
)
0.74
"These studies examined the influence of timing of administration of nateglinide on the glucose profile and beta-cell secretory response to a standardized test meal and the effect of meal composition on the pharmacokinetic and pharmacodynamic profile."( Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Anderson, DM; Luzio, SD; Owens, DR, 2001
)
0.74
"These data indicate that concomitant administration of diclofenac with nateglinide does not significantly alter the pharmacokinetic profile of either drug."( A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers.
Anderson, DM; Buraglio, M; Crick, N; Shelley, S, 2002
)
0.78
" Pharmacokinetic profiles were derived from plasma warfarin and nateglinide concentrations."( No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers.
Anderson, DM; Buraglio, M; Crick, N; Shelley, S, 2002
)
0.82
" This study evaluated the pharmacokinetic profile and safety of nateglinide, an amino acid derivative that improves early phase insulin secretion and reduces mealtime glucose excursions."( Pharmacokinetics of nateglinide in renally impaired diabetic patients.
Devineni, D; Lee, JS; McLeod, JF; Prasad, P; Smith, HT; Walter, YH, 2003
)
0.88
" Increasing evidence from receptor binding, mechanistic and in vitro and in vivo insulin studies indicate unique pharmacodynamic and pharmacokinetic properties with nateglinide that are distinct from those of sulphonylureas."( The mechanisms underlying the unique pharmacodynamics of nateglinide.
Boettcher, BR; Dunning, BE; Hu, S, 2003
)
0.76
" Mean pharmacokinetic parameters (AUC(0-6) 10."( Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
Inoue, T; Itahana, R; Izumi, M; Miyagawa, K; Nakanishi, T; Shibahara, N; Takamitsu, Y, 2003
)
0.64
" The pharmacokinetic and pharmacodynamic parameters of acenocoumarol were determined by noncompartmental analysis."( The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Bigler, H; Ligueros-Saylan, M; McLeod, J; Prasad, P; Smith, H; Sunkara, G; Wang, Y, 2004
)
0.68
" No significant pharmacokinetic alterations occur in renally impaired patients, in the elderly, or in mildly hepatically impaired patients."( Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod, JF, 2004
)
0.61
" Pharmacokinetic parameters of nateglinide were determined following the administration of nateglinide alone, and when administered in combination with sulfinpyrazone."( Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.
Ligueros-Saylan, M; McLeod, J; Prasad, P; Sabia, H; Smith, H; Sunkara, G; Wang, Y, 2004
)
0.85
" The time to reach Cmax (tmax) and the elimination half-life of nateglinide were similar between the two treatments."( Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.
Ligueros-Saylan, M; McLeod, J; Prasad, P; Sabia, H; Smith, H; Sunkara, G; Wang, Y, 2004
)
0.8
" grapefruit juice) may cause pharmacokinetic interactions."( Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen, AJ, 2007
)
0.56
" The present method was selective enough to analyze NTG in rabbit plasma without any tedious sample clean-up procedure and was successfully applied for estimating the pharmacokinetic parameters of NTG following oral administration of a single 15 mg NTG to white albino rabbits."( Nateglinide quantification in rabbit plasma by HPLC: optimization and application to pharmacokinetic study.
Mashru, RC; Sankalia, JM; Sankalia, MG; Sutariya, VB, 2007
)
1.78
" The quantitation method was successfully applied for simultaneous estimation of NTG, CLZ and DCLZ in a pharmacokinetic drug-drug interaction study in Wistar rats."( Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic
Kumar, VV; Potharaju, S; Sabapathi, SK; Satheeshmanikandan, TR; Shraddha, R; Sivakumar, SP; Sridhar, V; Varanasi, KK, 2008
)
0.55
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"The AUC(0-infinity) and Cmax of repaglinide were 32% (P=0."( Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Backman, JT; Kalliokoski, A; Neuvonen, PJ; Niemi, M, 2008
)
0.56

Compound-Compound Interactions

OATP 1B1 and OATP1B3 may have contributed to the hepatic uptake of nateglinide, but the possibility of drug-drug interactions appeared to be low. This open-label, prospective, multicentre, post-marketing surveillance study was conducted in China.

ExcerptReferenceRelevance
" Thus, drug-drug interactions involving transporters can often directly affect the therapeutic safety and efficacy of many drugs."( Food-drug interaction between ferulic acid and nateglinide involving the fluorescein/H+ cotransport system.
Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Kobayashi, Y; Kubo, S; Otsuka, Y, 2005
)
0.59
"This review describes the current knowledge on drug-drug and food-drug interactions with repaglinide and nateglinide."( Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen, AJ, 2007
)
0.77
"The aim of this work was to assess the efficacy and tolerability of nateglinide alone or in combination with metformin in elderly patients with type 2 diabetes (T2DM)."( Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Baron, MA; Gerich, JE; Jean-Louis, L; Marcellari, A; Purkayastha, D; Schwarz, SL, 2008
)
2.02
" Study 2 was a 104-week, multicentre, randomized, double blind and active-controlled study of nateglinide (120 mg, before meals) or glyburide (up to 5 mg bid) in combination with metformin (up to 1000 mg bid) in 69 treatment-naïve patients with T2DM aged >or=65 years."( Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Baron, MA; Gerich, JE; Jean-Louis, L; Marcellari, A; Purkayastha, D; Schwarz, SL, 2008
)
2.01
"Initial drug treatment with nateglinide, alone or in combination with metformin, is well tolerated and produces clinically meaningful improvements in glycaemic control in elderly patients with T2DM."( Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Baron, MA; Gerich, JE; Jean-Louis, L; Marcellari, A; Purkayastha, D; Schwarz, SL, 2008
)
2.08
"We have investigated the contributions of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to the hepatic uptake of nateglinide, and the possibility of drug-drug interactions via these transporters."( Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters.
Arisaka, H; Kubo, S; Shinkai, K; Takanohashi, T; Ubukata, K, 2012
)
0.8
" Inhibition studies using cryopreserved human hepatocytes were performed to examine the possibility of drug-drug interactions."( Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters.
Arisaka, H; Kubo, S; Shinkai, K; Takanohashi, T; Ubukata, K, 2012
)
0.6
" The calculated 1 + I(in,max,u) /IC50 values for inhibition of OATP1B1 and OATP1B3 by nateglinide, and the inhibition of saturable uptake of nateglinide by ciclosporin, were all close to 1, indicating a low clinical risk of drug-drug interaction with nateglinide taken up via OATP1B1 and OATP1B3."( Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters.
Arisaka, H; Kubo, S; Shinkai, K; Takanohashi, T; Ubukata, K, 2012
)
0.82
"OATP1B1 and OATP1B3 may have contributed to the hepatic uptake of nateglinide, but the possibility of drug-drug interactions appeared to be low."( Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters.
Arisaka, H; Kubo, S; Shinkai, K; Takanohashi, T; Ubukata, K, 2012
)
0.83
" This open-label, prospective, multicentre, post-marketing surveillance study was conducted to investigate the efficacy and safety of nateglinide in combination with metformin in Chinese patients with type 2 diabetes (T2DM)."( Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
Wang, L; Yang, JK, 2013
)
2.04
"The risk assessment of organic anion transporting polypeptide (OATP) 1B1-mediated drug-drug interactions (DDIs) is an indispensable part of drug development."( Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
Izumi, S; Komori, T; Kusuhara, H; Maeda, K; Nozaki, Y; Sugiyama, Y; Takenaka, O, 2015
)
0.42
" We aimed to systematically screen for drugs that interact with the five most commonly used secretagogues-glipizide, glyburide, glimepiride, repaglinide, and nateglinide-to cause serious hypoglycemia."( Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017
)
0.65
" We first predicted the drug-drug interaction potential based on the pharmacokinetics of each secretagogue-precipitant pair."( Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017
)
0.46
"We predicted 34 pharmacokinetic drug-drug interactions with the secretagogues, nine moderate and 25 weak."( Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017
)
0.46
"The self-controlled case series design has the potential to be widely applicable to screening for drug-drug interactions that lead to adverse outcomes identifiable in healthcare databases."( Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017
)
0.46

Bioavailability

Study was to increase dissolution and bioavailability of Nateglinide by development of its microenvironmental pH-regulated ternary solid dispersion (MeSD)

ExcerptReferenceRelevance
"The effect on food on the bioavailability of SDZ DJN 608, a D-phenylalanine derivative, was investigated in three mature, male beagle dogs."( Effect of food on the bioavailability of SDZ DJN 608, an oral hypoglycemic agent, from a tablet and a liquid-filled capsule in the dog.
Au, S; Habucky, K; Karara, A; Labbadia, D; Tse, FL, 1996
)
0.29
" No significant difference in the area under curve (AUC) was observed between LC and T, the absolute bioavailability of both being complete in the fasting state."( Effect of food on the bioavailability of SDZ DJN 608, an oral hypoglycemic agent, from a tablet and a liquid-filled capsule in the dog.
Au, S; Habucky, K; Karara, A; Labbadia, D; Tse, FL, 1996
)
0.29
"Food had little effect on the absorption rate but significantly reduced the bioavailability of SDZ DJN 608 regardless of the dosage form."( Effect of food on the bioavailability of SDZ DJN 608, an oral hypoglycemic agent, from a tablet and a liquid-filled capsule in the dog.
Au, S; Habucky, K; Karara, A; Labbadia, D; Tse, FL, 1996
)
0.29
" The effect of food on their bioavailability is similar."( Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi, M, 1996
)
0.29
" Therefore, one possible mechanism accounting for the more rapid and short-lived hypoglycemic action of A-4166 in vivo, as compared with tolbutamide, may involve the reported differences in the bioavailability of A-4166."( Insulin secretion from isolated rat islets induced by the novel hypoglycemic agent A-4166, a derivative of D-phenylalanine.
Kikuchi, M; Niki, I; Oka, Y; Sakurada, M; Tsukuda, K, 1998
)
0.3
" Oral bioavailability was 72%, indicating only a modest first-pass effect."( Pharmacokinetics and metabolism of nateglinide in humans.
Chin, JA; Graham, ED; Mangold, JB; McLeod, JF; Orwig, BA; Rodriguez, LC; Shapiro, MJ; Weaver, ML, 2001
)
0.59
" The estimated bioavailability is 72%."( Nateglinide.
Halas, CJ, 2001
)
1.75
" The effects of a meal on the oral bioavailability and pharmacodynamic actions of nateglinide were investigated."( The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
Dunning, BE; Karara, AH; McLeod, JF, 1999
)
0.74
"To evaluate the bioavailability of nateglinide-hydroxypropyl-beta-cyclodextrin (HPCD) complex, a rapid and specific liquid chromatographic-tandem mass spectrometric method was developed and validated to determine nateglinide in rabbit serum."( Study on the bioavailability of nateglinide-hydroxypropyl-beta-cyclodextrin complex capsule in rabbits by liquid chromatographic-tandem mass spectrometry.
Chen, X; He, Z; Liu, X; Zhang, R; Zhao, C; Zhong, D, 2004
)
0.88
" The meal-related timing of administration of glinides and the potential influence of food and meal composition on their bioavailability may be important."( Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen, AJ, 2007
)
0.56
" An in vivo single oral administration study using normal beagle dogs showed the bioavailability value of the obtained nateglinide dry coated tablets against nateglinide immediate release tablets was 73."( Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs.
Makino, C; Okano, A; Sakai, H; Yabuki, A, 2009
)
0.96
"Although considerably less potent than specified DPP-IV inhibitors, the possibility that some of the beneficial actions of nateglinide are indirectly mediated through DPP-IV inhibition and increased bioavailability of GIP and other incretins merits consideration."( Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
Bell, PM; Duffy, NA; Flatt, PR; Green, BD; Lindsay, JR; McKillop, AM; O'Harte, FP; Patterson, S, 2009
)
0.86
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"P-glycoprotein (Pgp or ABCB1) is an ABC transporter protein involved in intestinal absorption, drug metabolism, and brain penetration, and its inhibition can seriously alter a drug's bioavailability and safety."( A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
Broccatelli, F; Carosati, E; Cruciani, G; Frosini, M; Goracci, L; Neri, A; Oprea, TI, 2011
)
0.37
"To meet the requirements for marketing a new generic product, this study was designed to compare the pharmacokinetic parameters and relative fasting bioavailability of new generic (test) formulation of nateglinide with the reference formulation of nateglinide in healthy Chinese male volunteers."( Relative fasting bioavailability of two formulations of nateglinide 60 mg in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study.
Chen, J; Hu, Y; Ma, J; Yu, C; Yuan, L; Zhang, Q; Zhu, Y; Zou, J, 2012
)
0.81
" The relative bioavailability of the test formulation was estimated to be 102."( Relative fasting bioavailability of two formulations of nateglinide 60 mg in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study.
Chen, J; Hu, Y; Ma, J; Yu, C; Yuan, L; Zhang, Q; Zhu, Y; Zou, J, 2012
)
0.63
" By inhibiting the metabolism of drugs, piperine improves the bioavailability of drugs."( Effect of piperine on antihyperglycemic activity and pharmacokinetic profile of nateglinide.
Bommineni, MR; Mullangi, R; Nadipelli, M; Sama, V; Yenumula, P, 2012
)
0.61
" To evaluate the bioavailability of nateglinide proniosome, a rapid, simple and sensitive HPLC method with photodiode array detection was developed and validated to determine nateglinide in rabbit plasma."( Maltodextrin based proniosomes of nateglinide: bioavailability assessment.
Biswas, N; Guha, A; Kuotsu, K; Sahoo, RK, 2014
)
0.96
" The purpose of study was to increase dissolution and bioavailability of Nateglinide by development of its microenvironmental pH-regulated ternary solid dispersion (MeSD)."( Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation.
Gaud, R; Jadhav, N; Wairkar, S, 2017
)
0.95
" Instead of mere transformation of the Nateglinide to its amorphous form as evidenced by DSC and XRPD, formation of a soluble carboxylate compound of Nateglinide in MeSD was predominantly responsible for dissolution and bioavailability enhancement."( Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation.
Gaud, R; Jadhav, N; Wairkar, S, 2017
)
0.99
" Accordingly, the aim of this work was to investigate the effect of niosomal encapsulation on intestinal absorption and oral bioavailability of nateglinide."( Niosomes for oral delivery of nateglinide: in situ-in vivo correlation.
El Maghraby, GM; El-Gizawy, SA; Osman, MA; Sultan, AA, 2018
)
0.97
"This study was undertaken to improve solubility and bioavailability of nateglinide by preparation of stable self-emulsifying solid dispersions (SESDs)."( Effect of semicrystalline polymers on self-emulsifying solid dispersions of nateglinide: in vitro and in vivo evaluation.
Subudhi, BB; Swain, RP, 2018
)
0.94
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Most remarkably, bioavailability of NAT has been increased markedly on coadministration with PIO, than when it was administered alone."( Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism.
Alam, SP; Basak, S; De, A; Dey, S; Ghosh, M; Hossain, T; Karmakar, T; Saha, A, 2020
)
0.82

Dosage Studied

Nateglinide absorption was faster when administered at -5 or -10 minutes relative to food. All enrolled patients received 120 mg of nateglinides three times daily within 15 minutes before meals together with metformin for 12 weeks.

ExcerptRelevanceReference
"Food had little effect on the absorption rate but significantly reduced the bioavailability of SDZ DJN 608 regardless of the dosage form."( Effect of food on the bioavailability of SDZ DJN 608, an oral hypoglycemic agent, from a tablet and a liquid-filled capsule in the dog.
Au, S; Habucky, K; Karara, A; Labbadia, D; Tse, FL, 1996
)
0.29
" The dose-response curve of the insulin secretion to glucose was shifted to the left side by AY-4166."( Ay-4166 increases the sensitivity of insulin secretion to glucose in isolated perfused rat pancreas.
Mokuda, O; Morimoto, S; Sakamoto, Y, 1998
)
0.3
" No statistically significant or clinically relevant alteration in pharmacokinetic parameters of nateglinide resulted from hepatic dysfunction, and it was well tolerated; therefore, adjustment of nateglinide dosage is not required in subjects with mild to moderate cirrhosis."( Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.
Choudhury, S; Filipek, R; Hirschberg, Y; Lasseter, K; McLeod, JF, 2000
)
0.81
" Only approximately 16% of the dose was excreted unchanged in urine after either dosing route."( Pharmacokinetics and metabolism of nateglinide in humans.
Chin, JA; Graham, ED; Mangold, JB; McLeod, JF; Orwig, BA; Rodriguez, LC; Shapiro, MJ; Weaver, ML, 2001
)
0.59
"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, interactions, and dosage of nateglinide are reviewed."( Nateglinide.
Halas, CJ, 2001
)
1.97
" In the first study premeal (-10,-1 min), administration of nateglinide led to earlier and higher peak plasma nateglinide concentrations, compared with postprandial dosing (+10 min)."( Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Anderson, DM; Luzio, SD; Owens, DR, 2001
)
0.75
"To review the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy of nateglinide."( Nateglinide therapy for type 2 diabetes mellitus.
Baker, DE; Campbell, RK; Levien, TL; White, JR, 2001
)
1.96
"Nateglinide is similar to repaglinide, but has a quicker onset of action, quicker reversal, and does not usually require dosage titration."( Nateglinide therapy for type 2 diabetes mellitus.
Baker, DE; Campbell, RK; Levien, TL; White, JR, 2001
)
3.2
" When used in a flexible dosing regime in a large cohort of patients, it is associated with better glycaemic control, a reduction in HbA1c, weight loss and improved quality of life compared to sulphonylureas."( Insulin secretagogues.
Davies, MJ, 2002
)
0.31
" On the sixth occasion, subjects received placebo tablets at all dosing time points."( The effect of nateglinide taken with food on gastric emptying rates in healthy subjects.
Anderson, D; Kellett, N; Marshall, D; Nimmo, W; Shelley, S, 2003
)
0.68
" Nateglinide absorption was faster when administered at -5 or -10 minutes relative to food, as characterized by higher nateglinide area under the concentration-time curve from 0 to 5 hours (AUC(0-5)) and maximum plasma concentration (C(max)) values, compared with those observed at other dosing time points."( The effect of nateglinide taken with food on gastric emptying rates in healthy subjects.
Anderson, D; Kellett, N; Marshall, D; Nimmo, W; Shelley, S, 2003
)
1.59
" The decision to prescribe one of these three insulinotropic agents should be based on factors such as the patient's ability to comply with complex dosing regimens, the need to control fasting hyperglycemia, the risk of interprandial hypoglycemia, and pharmacoeconomic considerations, rather than postprandial glucose-lowering efficacy."( Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Carroll, MF; Castro, M; Gutierrez, A; Schade, DS; Tsewang, D, 2003
)
0.32
" This suggests that no dosage adjustments will be required when nateglinide and acenocoumarol are coadministered in clinical practice."( The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Bigler, H; Ligueros-Saylan, M; McLeod, J; Prasad, P; Smith, H; Sunkara, G; Wang, Y, 2004
)
0.92
" The objective was to compare glucose, insulin and C-peptide 24 h profiles in patients with type 2 diabetes mellitus after dosing with nateglinide (given preprandially before three test meals), glibenclamide (administered once before breakfast) or placebo (given before three test meals)."( A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
Anderson, DM; Barnett, AH; Morgan, R; Owens, DR; Shelley, S, 2004
)
0.77
" Dosing followed a six-sequence balanced, two 3 x 3-replicated Latin square."( A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
Anderson, DM; Barnett, AH; Morgan, R; Owens, DR; Shelley, S, 2004
)
0.56
"The objective of this study is to formulate lyophilized oral sustained release polymeric nanoparticles of nateglinide in order to decrease dosing frequency, minimize side effects, and increase bioavailability."( Lyophilized oral sustained release polymeric nanoparticles of nateglinide.
Kaleemuddin, M; Srinivas, P, 2013
)
0.84
" All enrolled patients received 120 mg of nateglinide three times daily within 15 minutes before meals together with metformin (with no restrictions on dosage or frequency of administration) for 12 weeks."( Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
Wang, L; Yang, JK, 2013
)
2.1
" The main problem in formulating an oral dosage form is its low solubility in aqueous media."( I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing.
Bruni, G; Canobbio, A; Cardini, A; Conte, U; Maggi, L; Maietta, M, 2013
)
0.63
"Selective and straightforward kinetic spectrophotometric methods were developed to quantify nateglinide (NTG) in pharmaceutical dosage forms."( Optimized Box-Behnken experimental design based response surface methodology and Youden's robustness test to develop and validate methods to determine nateglinide using kinetic spectrophotometry.
Haque, SM, 2022
)
1.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenylalanine derivativeAn amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of phenylalanine by a heteroatom. The definition normally excludes peptides containing phenylalanine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency19.01150.007215.758889.3584AID588342
GALC proteinHomo sapiens (human)Potency3.548128.183828.183828.1838AID1159614
TDP1 proteinHomo sapiens (human)Potency21.13600.000811.382244.6684AID686978
AR proteinHomo sapiens (human)Potency10.86370.000221.22318,912.5098AID1259243; AID743042
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency13.33320.001022.650876.6163AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency19.95260.01237.983543.2770AID1346984
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.31380.000229.305416,493.5996AID743075
GVesicular stomatitis virusPotency27.54040.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency29.84700.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00530.023723.228263.5986AID743222
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency26.60320.001723.839378.1014AID743083
Interferon betaHomo sapiens (human)Potency27.54040.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)104.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Ki9.20001.60005.744010.0000AID598879; AID679148
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (86)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (111)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID678853TP_TRANSPORTER: uptake in PEPT2-expressing LLC-PK1 cells2000European journal of pharmacology, Mar-24, Volume: 392, Issue:1-2
Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2.
AID364053Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells at 100 uM after 1 hr relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID669729Insulinotropic activity in rat INS1(833/15) cells assessed as increase in insulin secretion at 10 uM after 2 hrs by competitive enzyme immunoassay in the presence of 16 mM glucose2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID679846TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002British journal of pharmacology, Oct, Volume: 137, Issue:3
Transport and uptake of nateglinide in Caco-2 cells and its inhibitory effect on human monocarboxylate transporter MCT1.
AID598252Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 at 0.1 mM after 20 mins by FACS analysis relative to 5 mM sodium orthovanadate2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588058Hypoglycemic activity in healthy Sprague-Dawley rat assessed as normal fasting plasma glucose level at 50 mg/kg, po2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID82573Insulin-releasing activity in HIT-T15 cells in the presence of 16.7 mM glucose at 10 uM expressed as percent activity of nateglinide2000Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21
Hybridization of non-sulfonylurea insulin secretagogue and thiazolidinedione-derived insulin sensitizer.
AID706694Antihyperglycemic activity in streptozotocin-induced diabetic Sprague-Dawley rat assessed as reduction in blood glucose level at 63.01 umol/kg, po after 6 hrs relative to control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: in-vivo antihyperglycemic activities and blood pressure lowering studies.
AID364052Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells at 10 uM after 1 hr relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID132162Hypoglycemic activity causing more than a 20% blood glucose decrease in fasting mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2.
AID679864TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing LLC-PK1 cells2000European journal of pharmacology, Mar-24, Volume: 392, Issue:1-2
Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2.
AID679148TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes2000European journal of pharmacology, Jun-16, Volume: 398, Issue:2
Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID364054Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells after 1 hr2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588061Hypoglycemic activity in healthy Sprague-Dawley rat assessed as plasma insulin level at 50 mg/kg, po2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID669728Insulinotropic activity in rat INS1(833/15) cells assessed as increase in insulin secretion at 10 uM after 2 hrs by competitive enzyme immunoassay in the presence of 11 mM glucose2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID598251Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 after 20 mins by FACS analysis2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1191475Hypoglycemic activity in STZ-treated Wistar rat diabetic model at 50 mg/kg, ip after 10 mins treated with 1 g/kg, ip glucose2015Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
Synthesis and evaluation of multi-functional NO-donor/insulin-secretagogue derivatives for the treatment of type II diabetes and its cardiovascular complications.
AID678719Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678881TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT2-expressing LLC-PK1 cells2000European journal of pharmacology, Mar-24, Volume: 392, Issue:1-2
Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2.
AID364051Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells at 1 uM after 1 hr relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID3420Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone2000Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21
Hybridization of non-sulfonylurea insulin secretagogue and thiazolidinedione-derived insulin sensitizer.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID598879Inhibition of rat Oat1 expressed in Xenopus oocytes2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1).
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID3419Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone2000Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21
Hybridization of non-sulfonylurea insulin secretagogue and thiazolidinedione-derived insulin sensitizer.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID706696Antihyperglycemic activity in streptozotocin-induced diabetic Sprague-Dawley rat assessed as reduction in blood glucose level at 63.01 umol/kg, po after 1 hr relative to control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: in-vivo antihyperglycemic activities and blood pressure lowering studies.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID679848TP_TRANSPORTER: uptake in PEPT1-expressing LLC-PK1 cells2000European journal of pharmacology, Mar-24, Volume: 392, Issue:1-2
Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID669725Insulinotropic activity in rat INS1(833/15) cells assessed as increase in insulin secretion at 10 uM after 2 hrs by competitive enzyme immunoassay in the presence of low concentration of glucose2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
AID706695Antihyperglycemic activity in streptozotocin-induced diabetic Sprague-Dawley rat assessed as reduction in blood glucose level at 63.01 umol/kg, po after 3 hrs relative to control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: in-vivo antihyperglycemic activities and blood pressure lowering studies.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID132163Percent decrease in blood glucose level, after peroral administration of 100 mg/kg of compound in mice; Inactive1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (420)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.24)18.7374
1990's40 (9.52)18.2507
2000's240 (57.14)29.6817
2010's110 (26.19)24.3611
2020's29 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.65 (24.57)
Research Supply Index6.32 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index121.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (71.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials112 (25.40%)5.53%
Reviews66 (14.97%)6.00%
Case Studies8 (1.81%)4.05%
Observational4 (0.91%)0.25%
Other251 (56.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
RANDOMIZED, 2-WAY CROSSOVER, BIOEQUIVALENCE STUDY OF NATEGLINIDE 120 mg TABLET AND STARLIX@ ADMINISTERED AS 1 x 120 mg TABLET IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS [NCT01159158]Phase 168 participants (Actual)Interventional2007-02-28Completed
Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study [NCT02456428]1,499,650 participants (Actual)Observational2014-03-31Completed
The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes [NCT02476760]1,417,914 participants (Actual)Observational2014-03-31Completed
[NCT02088918]Phase 140 participants (Actual)Interventional2012-10-31Completed
RANDOMIZED, 2-WAY CROSSOVER, BIOEQUIVALENCE STUDY OF NATEGLINIDE 120 mg TABLET AND STARLIX@ ADMINISTERED AS 1 x 120 mg TABLET IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS [NCT01160029]Phase 158 participants (Actual)Interventional2004-10-31Completed
A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients [NCT00928889]Phase 4160 participants (Actual)Interventional2009-07-31Completed
A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus [NCT01030952]Phase 4103 participants (Actual)Interventional2009-12-31Completed
[NCT00189774]Phase 2/Phase 30 participants InterventionalCompleted
Phase IV Study on Predictive Markers for the Effectiveness of Nateglinide or Acarbose for Controlling Post-Prandial Glucose in Type 2 Diabetics Already on Optimized Insulin Glargine Therapy [NCT00437918]Phase 485 participants (Actual)Interventional2007-01-31Completed
Insulin Resistance and Postprandial Endothelial Function: Does Early Intervention Make a Difference? [NCT00259168]Phase 470 participants (Actual)Interventional2003-06-30Completed
Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance [NCT00319189]Phase 415 participants Interventional2002-11-30Completed
A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Compare the Safety and Efficacy of Nateglinide vs. Placebo in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Basal Insulin Glargine in Combin [NCT00402909]Phase 428 participants (Actual)Interventional2006-11-30Completed
Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination With Nateglinide in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Wit [NCT01316107]Phase 3122 participants (Actual)Interventional2011-01-15Completed
[NCT00212290]Phase 4140 participants (Anticipated)Interventional2002-11-30Completed
Multi-center, Randomized, Open Label Study of the Durability of Glycemic Control With Nateglinide Versus Glimepiride as Monotherapy in Type 2 Diabetic Patients [NCT00858013]Phase 488 participants (Actual)Interventional2009-04-24Completed
Evaluation of Usefulness of Combination Therapy of Rapid Acting Insulin Secretagogue (Glinide) With Premixed Insulin in Type 2 Diabetes [NCT00369148]Phase 460 participants Interventional2004-07-31Completed
A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion [NCT00238472]Phase 424 participants Interventional2003-05-31Completed
A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in [NCT00097786]Phase 39,306 participants (Actual)Interventional2002-01-31Completed
The Use of Incretin-based Drugs and the Risk of Pancreatic Cancer in Patients With Type 2 Diabetes [NCT02475499]886,172 participants (Actual)Observational2014-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00097786 (6) [back to overview]Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan
NCT00097786 (6) [back to overview]Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide
NCT00097786 (6) [back to overview]Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartan
NCT00097786 (6) [back to overview]Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide
NCT00097786 (6) [back to overview]Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartan
NCT00097786 (6) [back to overview]Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Nateglinide Versus Non-nateglinide
NCT00858013 (5) [back to overview]C-peptide
NCT00858013 (5) [back to overview]The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate
NCT00858013 (5) [back to overview]HOMA-IR
NCT00858013 (5) [back to overview]HbA1c
NCT00858013 (5) [back to overview]Fasting Glucose
NCT00928889 (10) [back to overview]Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Free Fatty Acids (FFA) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Total Cholesterol at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Triglycerides at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Peak Postprandial Glucose at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Postprandial Glucose Area Under the Curve at the End of the Study (Week 4)
NCT01030952 (15) [back to overview]Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
NCT01030952 (15) [back to overview]Change in Insulin Levels (μU/ml) During Standardized Meal Test at Endpoint From Baseline
NCT01030952 (15) [back to overview]Change in Triglyceride (TG)Levels in Blood Lipid Levels During Standardized Meal Test at Endpoint
NCT01030952 (15) [back to overview]Change of Total Cholesterol in Blood Lipids Levels During Standardized Meal Test at Endpoint From Baseline at Each Time Point
NCT01030952 (15) [back to overview]Change in Standard Deviation (SD) From Baseline of Mean Blood Glucose (MBG) Over 24 Hours.
NCT01030952 (15) [back to overview]Change in Percent of 24 Hour Hyperglycemic Measurements
NCT01030952 (15) [back to overview]Change in Mean of Daily Difference of Paired Blood Glucose Value (MODD)
NCT01030952 (15) [back to overview]Change in Mean Blood Glucose (MBG)
NCT01030952 (15) [back to overview]Change in Mean Amplitude of Glycaemic Excursion (MAGE)
NCT01030952 (15) [back to overview]Change in Incremental Glucose Peak (IGP) From Baseline
NCT01030952 (15) [back to overview]Change in Glycated Serum Albumin (GSA) Levels From Baseline After Treatment
NCT01030952 (15) [back to overview]Change in Area Under Curve of 0-4 Hours Postprandial Glucose (AUCpp0-4hours) in Standardized Meal Test Using Continuous Glucose Monitoring System (CGMS)
NCT01030952 (15) [back to overview]The Percent of 24 Hour Hypoglycemic Measurements
NCT01030952 (15) [back to overview]Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study
NCT01030952 (15) [back to overview]Changes in 24 Hour Glucose Area Under Curve (AUCpp)

Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan

Progression to diabetes was determined by (a) an algorithm based on central laboratory measurements of fasting plasma glucose and/or a 2 hour oral glucose tolerance test or (b) adjudication by the Diabetes Endpoint Adjudication Committee. (NCT00097786)
Timeframe: Mean patient duration of 4.2 years

InterventionPercentage of patients (Number)
Valsartan33.1
Non-valsartan36.8

[back to top]

Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide

The extended cardiovascular endpoint was defined as a cardiovascular morbidity/mortality event including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, revascularization procedure, hospitalization for congestive heart failure, and hospitalization for unstable angina. (NCT00097786)
Timeframe: Mean patient duration of 5.6 years

InterventionPercentage of patients (Number)
Nateglinide14.2
Non-nateglinide15.2

[back to top]

Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartan

The core cardiovascular endpoint was defined as a cardiovascular morbidity/mortality event including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure. (NCT00097786)
Timeframe: Mean patient duration of 5.8 years

InterventionPercentage of patients (Number)
Valsartan8.1
Non-valsartan8.1

[back to top]

Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide

The core cardiovascular endpoint was defined as a cardiovascular morbidity/mortality event including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure. (NCT00097786)
Timeframe: Mean patient duration of 5.8 years

InterventionPercentage of patients (Number)
Nateglinide7.9
Non-nateglinide8.3

[back to top]

Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartan

The extended cardiovascular endpoint was defined as a cardiovascular morbidity/mortality event including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, revascularization procedure, hospitalization for congestive heart failure, and hospitalization for unstable angina. (NCT00097786)
Timeframe: Mean patient duration of 5.6 years

InterventionPercentage of patients (Number)
Valsartan14.5
Non-valsartan14.8

[back to top]

Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Nateglinide Versus Non-nateglinide

Progression to diabetes was determined by (a) an algorithm based on central laboratory measurements of fasting plasma glucose and/or a 2 hour oral glucose tolerance test or (b) adjudication by the Diabetes Endpoint Adjudication Committee. (NCT00097786)
Timeframe: Mean patient duration of 4.2 years

InterventionPercentage of patients (Number)
Nateglinide36.0
Non-nateglinide33.9

[back to top]

C-peptide

c-peptide(uU/mL) at 24 months (NCT00858013)
Timeframe: at 24 months

InterventionuU/mL (Mean)
Nateglinide1.29
Glimepiride1.77

[back to top]

The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate

% monotherapy failure, that means % number of participants who withdrew from the study due to high HbA1c (>8.0%) (NCT00858013)
Timeframe: every 3 months following randomization, for 24 months

InterventionParticipants (Count of Participants)
Nateglinide10
Glimepiride7

[back to top]

HOMA-IR

insulin resistance marker HOMA-IR at 24 months (NCT00858013)
Timeframe: at 24 months

Interventionmg/dL x mIU/L (Mean)
Nateglinide2.40
Glimepiride2.31

[back to top]

HbA1c

HbA1c (%) at 24 months (NCT00858013)
Timeframe: at 24 months

Intervention% HbA1c (Mean)
Nateglinide6.9
Glimepiride6.5

[back to top]

Fasting Glucose

fasting glucose (mg/dL) at 24 months (NCT00858013)
Timeframe: at 24 months

Interventionmg/dL (Mean)
Nateglinide131.2
Glimepiride115.7

[back to top]

Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4)

Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. PPGE was defined as the mean difference between the preprandial glucose value and the postprandial glucose value measured at 2 hours in a standardized meal test. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

Interventionmmol/L (Mean)
Nateglinide 120 mg-1.775
Acarbose 50 mg-2.434

[back to top]

Change From Baseline in Free Fatty Acids (FFA) at the End of the Study (Week 4)

Blood samples were collected for measurement of FFA prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. FFA was assayed at a central laboratory. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmmol/L (Mean)
Fasting, N=73, 7530 minutes, N=73, 7560 minutes, N=72, 7590 minutes, N=72, 75120 minutes, N=73, 75
Acarbose 50 mg-0.040-0.048-0.048-0.042-0.034
Nateglinide 120 mg-0.048-0.112-0.224-0.109-0.099

[back to top]

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study (Week 4)

Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. HDL-C was assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmmol/L (Mean)
Fasting, N=74, 77120 minutes, N=74, 76
Acarbose 50 mg-0.0390.003
Nateglinide 120 mg0.0200.023

[back to top]

Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at the End of the Study (Week 4)

Blood samples were collected for measurement of hsCRP prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. hsCRP was assayed at a central laboratory. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmg/dL (Mean)
Fasting, N=73, 7530 minutes, N=73, 7560 minutes, N=72, 7590 minutes, N=72, 75120 minutes, N=72, 74
Acarbose 50 mg0.0800.0240.0710.0770.074
Nateglinide 120 mg-0.229-0.227-0.219-0.220-0.218

[back to top]

Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4)

Blood samples were collected for measurement of LDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. LDL-C was assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmmol/L (Mean)
Fasting, N=74, 77120 minutes, N=74, 76
Acarbose 50 mg0.0360.044
Nateglinide 120 mg0.036-0.000

[back to top]

Change From Baseline in Total Cholesterol at the End of the Study (Week 4)

Blood samples were collected for measurement of total cholesterol prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. Total cholesterol was assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmmol/L (Mean)
Fasting, N=74, 77120 minutes, N=74, 76
Acarbose 50 mg-0.149-0.059
Nateglinide 120 mg0.0150.010

[back to top]

Change From Baseline in Triglycerides at the End of the Study (Week 4)

Blood samples were collected for measurement of triglycerides prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. Triglycerides were assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmmol/L (Mean)
Fasting, N=74, 77120 minutes, N=74, 76
Acarbose 50 mg-0.418-0.396
Nateglinide 120 mg-0.0100.026

[back to top]

Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4)

Blood samples were collected for measurement of GSA prior to (fasting) the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. GSA was assayed at a central laboratory. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

InterventionPercentage (Mean)
Nateglinide 120 mg-1.2
Acarbose 50 mg-1.2

[back to top]

Change From Baseline in Peak Postprandial Glucose at the End of the Study (Week 4)

Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The peak postprandial glucose values were used in the calculation of change from Baseline at Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

Interventionmmol/L (Mean)
Nateglinide 120 mg-2.350
Acarbose 50 mg-3.129

[back to top]

Change From Baseline in Postprandial Glucose Area Under the Curve at the End of the Study (Week 4)

Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

Interventionmmol*min/L (Mean)
Nateglinide 120 mg-217.628
Acarbose 50 mg-278.447

[back to top]

Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

change in LDL-C at 0, 30 and 120 minutes (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

,
Interventionmillimoles per litre (mmol/l) (Mean)
0 minutes30 minutes120 minutes
Acarbose0.0640.090.13
Nateglinide-0.04-0.06-0.04

[back to top]

Change in Insulin Levels (μU/ml) During Standardized Meal Test at Endpoint From Baseline

This outcome measure calculated the change in insulin levels between groups over time at 0, 30 then 120 minutes (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

,
Intervention(μU/ml) (Mean)
0 minutes30 minutes120 minutes
Acarbose-0.21-6.64-16.24
Nateglinide0.3213.8715.03

[back to top]

Change in Triglyceride (TG)Levels in Blood Lipid Levels During Standardized Meal Test at Endpoint

TG change in blood lipids level from baseline to endpoint (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

,
Interventionmillimoles per litre (mmol/l) (Mean)
0 minutes30 minutes120 minutes
Acarbose-0.48-0.39-0.47
Nateglinide-0.19-0.23-0.19

[back to top]

Change of Total Cholesterol in Blood Lipids Levels During Standardized Meal Test at Endpoint From Baseline at Each Time Point

time to change in Total Cholesterol blood lipids level at 0, 30, 120 minutes (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

,
Interventionmillimoles per litre (mmol/l) (Mean)
0 minutes30 minutes120 minutes
Acarbose-0.090.560.03
Nateglinide-0.03-0.06-0.01

[back to top]

Change in Standard Deviation (SD) From Baseline of Mean Blood Glucose (MBG) Over 24 Hours.

Change in standard deviation (SD) from baseline of mean blood glucose (MBG) describes the range of blood glucose fluctuation over 24 hours. (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionmmol/l (Mean)
Nateglinide-0.48
Acarbose-0.63

[back to top]

Change in Percent of 24 Hour Hyperglycemic Measurements

Measures/compares changes in percentage of hyperglycemia (>7.8mmol/l or 140 mg/dl) in glucose measurements in 24 hours by continuous glucose monitoring system (CGMS) at endpoint from baseline between groups. Reported values are percent change of the base absolute values [100% * ((X-Y)/Y)] (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionpercent of measurements (Mean)
Nateglinide-50.83
Acarbose-33.82

[back to top]

Change in Mean of Daily Difference of Paired Blood Glucose Value (MODD)

The mean of the daily differences (MODD), calculated as the average absolute difference of paired glucose values during two successive 24 hour periods, was used to assess day-to-day glycaemic variability. (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionmillimoles per litre (mmol/l) (Mean)
Nateglinide-0.06
Acarbose-0.21

[back to top]

Change in Mean Blood Glucose (MBG)

The 24 hour mean blood glucose (MBG) level was calculated as the mean of all the consecutive readings on baseline and end of study(3 weeks later) separately. (NCT01030952)
Timeframe: baseline and at 3 weeks (end of study)

Interventionmillimoles per litre (mmol/l) (Mean)
Nateglinide-1.16
Acarbose-0.78

[back to top]

Change in Mean Amplitude of Glycaemic Excursion (MAGE)

mean amplitude of glycaemic excursion (MAGE) is an average of the amplitudes of all glycemic excursions greater than a prespecified threshold size (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionmmol/l (Mean)
Nateglinide5.27
Acarbose5.03

[back to top]

Change in Incremental Glucose Peak (IGP) From Baseline

Incremental glucose peak (IGP) was the maximal incremental increase in blood glucose obtained at any point after meal (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionmillimoles per litre (mmol/L) (Mean)
Nateglinide-2.72
Acarbose-1.89

[back to top]

Change in Glycated Serum Albumin (GSA) Levels From Baseline After Treatment

GSA levels were to be determined by CGMS at 7:00~10:00 am in the 4-hour standardized meal test before treatment after overnight fasting for efficacy assessments (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionpercent (Mean)
Nateglinide-2.22
Acarbose-1.74

[back to top]

Change in Area Under Curve of 0-4 Hours Postprandial Glucose (AUCpp0-4hours) in Standardized Meal Test Using Continuous Glucose Monitoring System (CGMS)

"The postprandial glucose area under the curve (AUC)was calculated using values from the 3 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.~0-4 hours AUC were calculated using trapezoid methods." (NCT01030952)
Timeframe: 3 weeks (end of study) minus baseline

Interventionmillimoles hours per litre (mmol*hr/L) (Least Squares Mean)
Nateglinide-9.20
Acarbose-9.92

[back to top]

The Percent of 24 Hour Hypoglycemic Measurements

Measures/compares changes in percentage of hypoglycemia(<3.9mmol/l or <70 mg/dl) in glucose measurements in 24hours by continuous glucose monitoring system (CGMS) at endpoint from baseline between groups. Reported values are percent change of the base absolute values [100% * ((X-Y)/Y)] (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionpercent of measurements (Mean)
Nateglinide0.82
Acarbose-0.57

[back to top]

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study

Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 3. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. HDL-C was assessed at each study site using the same method and same reference value. (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

,
Interventionmillimoles per litre (mmol/l) (Mean)
0 minutes30 minutes120 minutes
Acarbose-0.020.010.00
Nateglinide0.200.020.03

[back to top]

Changes in 24 Hour Glucose Area Under Curve (AUCpp)

Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT01030952)
Timeframe: baseline, end of study (3 weeks)

Interventionmmol*min/L (Mean)
Nateglinide-1.16
Acarbose-0.78

[back to top]